Top Page
Rhythm Biosciences Ltd.
(Sydney:RHY)
Rhythm Biosciences Ltd. (RHY) vs. iShares MSCI Australia ETF (EWA)
Rhythm Biosciences Ltd. Business Overview & Revenue Model
Rhythm Biosciences Ltd. Financial Statement Overview
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 5.59M | 1.69M | 3.10M | 2.43M | 1.11M | 100.00K | Gross Profit |
| 4.02M | -1.36M | 2.91M | 2.33M | 961.86K | -41.29K | EBIT |
| -3.50M | -6.71M | -11.54M | -11.25M | -6.61M | -4.02M | EBITDA |
| -2.02M | -6.80M | -11.11M | -11.10M | -6.47M | -3.87M | Net Income Common Stockholders |
| -2.18M | -6.86M | -8.22M | -6.32M | -7.72M | -4.13M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 4.45M | 754.50K | 4.17M | 7.60M | 2.27M | 1.84M | Total Assets |
| 5.93M | 1.52M | 7.70M | 8.44M | 3.07M | 2.65M | Total Debt |
| 158.66K | 163.82K | 84.61K | 170.14K | 0.00 | 42.44K | Net Debt |
| -4.21M | -545.67K | -4.04M | -7.38M | -2.23M | -1.76M | Total Liabilities |
| 1.05M | 651.54K | 1.82M | 1.07M | 1.36M | 802.85K | Stockholders Equity |
| 4.88M | 867.17K | 5.87M | 7.37M | 1.71M | 1.84M |
| Cash Flow | Free Cash Flow | ||||
| -2.12M | -6.22M | -7.06M | -6.24M | -5.47M | -2.79M | Operating Cash Flow |
| -2.12M | -6.14M | -6.96M | -6.21M | -5.40M | -2.74M | Investing Cash Flow |
| -561.35K | -82.28K | -99.12K | -27.01K | -68.27K | -45.53K | Financing Cash Flow |
| 5.83M | 2.80M | 3.63M | 11.85M | 5.90M | -142.22K |
Rhythm Biosciences Ltd. Technical Analysis
Rhythm Biosciences Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | AU$54.91B | 27.98 | 25.23% | 0.82% | 10.54% | 38.69% | |
76 Outperform | $1.38B | 81.32 | 9.23% | ― | 10.79% | 5.20% | |
72 Outperform | $17.83B | 48.19 | 20.61% | 1.68% | 6.35% | 5.97% | |
64 Neutral | $119.30B | 28.63 | 15.38% | 1.70% | 8.00% | 9.09% | |
53 Neutral | $5.14B | 3.23 | -45.01% | 2.85% | 17.55% | -0.69% | |
45 Neutral | AU$17.68M | ― | -71.10% | ― | ― | 76.17% |
Rhythm Biosciences Ltd. Corporate Events
Rhythm Biosciences Ltd has successfully completed the verification and validation of its second-generation ColoSTAT® assay Beta kits, marking a significant step towards commercialization. The optimized kits, designed for routine lab use, have demonstrated improved performance, reduced turnaround times, and cost efficiency. The company is now transitioning to the final manufacturing stage with its partner Quansys, aiming for commercial availability following further testing and accreditation. This advancement strengthens Rhythm’s position in the cancer diagnostics industry and promises to enhance colorectal cancer detection, potentially reducing mortality and healthcare costs.
Rhythm Biosciences Ltd has announced a 12-month contract through its subsidiary Genetype with the University of Melbourne to provide geneType™ Breast Cancer Risk assessment. This partnership aims to enhance breast cancer screening for Australian women aged 40-59 by integrating personalized risk assessment approaches, which align with national guidelines. The study will incorporate factors like family history, mammographic breast density, and polygenic risk scores, potentially setting a new standard for risk-stratified screening. This collaboration not only accelerates Genetype’s commercial growth but also strengthens its market position in predictive cancer diagnostics, offering significant implications for stakeholders by potentially improving the effectiveness of breast cancer screening and expanding the use of personalized risk models.
Rhythm Biosciences Ltd. announced the issuance of 401,716 unquoted securities, specifically options expiring on March 31, 2026, with an exercise price of $0.20. This issuance is part of previously announced transactions and is not intended to be quoted on the ASX. The move reflects the company’s ongoing strategic financial maneuvers to support its operations and growth within the biotechnology sector, potentially impacting its market positioning and stakeholder interests.
Rhythm Biosciences Ltd. announced a proposed issue of securities, specifically options expiring on March 31, 2026, with an exercise price of $0.20. This issuance, involving a total of 401,716 securities, is aimed at raising capital to support the company’s operational and strategic initiatives. The announcement reflects the company’s ongoing efforts to strengthen its financial position and enhance its market presence in the biotechnology sector.
Rhythm Biosciences Ltd has announced significant progress in its ColoSTAT® Beta kits, which are in the final verification phase and preparing for clinical validation. The company has also successfully integrated the Genetype business and relaunched the geneType™ product portfolio, achieving its first commercial sales. These developments, alongside strategic management enhancements, position Rhythm Biosciences to strengthen its operations and market presence, with expectations for further milestones in the upcoming quarters.
Rhythm Biosciences Ltd has successfully maintained its ISO 13485:2016 certification for the seventh consecutive year, with an extended scope that now includes hardware development as part of its ColoSTAT® system. This certification supports the company’s market entry strategy by enhancing regulatory approvals and market confidence, reinforcing its operational credibility, and validating its robust quality systems. The certification is crucial for the international launch of ColoSTAT® and the company’s ability to supply high-quality raw materials for in-house IVD applications.
Rhythm Biosciences Ltd. has announced the application for the quotation of new securities on the Australian Securities Exchange (ASX). The company is set to quote 33,333,331 options expiring on March 31, 2026, as part of previously announced transactions. This move could potentially enhance the company’s financial flexibility and support its ongoing projects in the biotechnology sector.
Rhythm Biosciences Ltd. has seen a change in its substantial holdings, with FIL Limited increasing its voting power from 5.04% to 6.04% as of April 4, 2025. This increase in shares reflects a strategic move by FIL Limited, potentially signaling confidence in Rhythm Biosciences’ market position and future prospects, which could have implications for stakeholders and the company’s operations.
Rhythm Biosciences Ltd announced that all resolutions at their Extraordinary General Meeting were successfully passed. This outcome reflects strong shareholder support and is expected to positively impact the company’s strategic initiatives and market positioning, particularly in the field of cancer diagnostics.
Rhythm Biosciences Ltd. has released an investor presentation highlighting its ongoing efforts in the biotechnology sector, particularly in cancer diagnostics. The presentation serves as a general information guide and includes forward-looking statements subject to change, emphasizing the company’s commitment to advancing its research and development initiatives. Stakeholders are advised to consider the inherent uncertainties and risks associated with the company’s projections.
Rhythm Biosciences Ltd has announced the first commercial sales of its geneType™ products following the acquisition of Genetype in December 2024. The company anticipates significant sales growth driven by enterprise market focus, geographic expansion, and support from key opinion leaders. The geneType™ platform offers comprehensive risk assessments for various diseases, positioning Rhythm well in the preventative healthcare market. The company also plans to expand revenues with ColoSTAT® sales in the next financial year, further strengthening its market position.
Rhythm Biosciences Ltd. announced the issuance of 750,000 unquoted securities under an employee incentive scheme, which are not intended to be quoted on the ASX. This move is part of the company’s strategy to incentivize employees, potentially impacting its operational efficiency and stakeholder engagement by aligning employee interests with company performance.
Rhythm Biosciences Ltd has announced the appointment of Todd Perkinson as the new Chief Financial Officer. Perkinson brings extensive experience in financial management and business transformation, having successfully led major mergers, acquisitions, and business turnarounds in previous roles. His appointment comes as Rhythm prepares for significant global growth, indicating a strategic move to enhance its financial leadership and operational efficiency. This development is expected to strengthen Rhythm’s industry positioning and support its mission to expand its innovative cancer diagnostics solutions globally.
Rhythm Biosciences Ltd. announced the cessation of 1,000,000 ordinary fully paid employee securities due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This announcement may impact the company’s capital structure and could have implications for employee incentives and stakeholder confidence.
Rhythm Biosciences Limited has released an investor presentation, emphasizing that the information provided is for general purposes and not intended as investment advice. The presentation includes forward-looking statements subject to risks and uncertainties, and the company disclaims any liability for the accuracy or completeness of the information, which may change based on further research.
Rhythm Biosciences Limited has announced an Extraordinary General Meeting to be held on March 31, 2025, at the Offices of K&L Gates in Melbourne, Victoria. This hybrid meeting will allow shareholders to participate both in person and online. The meeting is crucial as it affects shareholder voting rights, and the company encourages shareholders to vote either in person or by proxy to ensure their voices are heard.
Rhythm Biosciences Ltd announced an investor webinar to discuss their half-year report, progress on the ColoSTAT® test for colorectal cancer detection, and the integration of Genetype assets. The ColoSTAT® test, a simple blood-based test, aims to provide an alternative for those unable or unwilling to participate in current screening programs, potentially reducing mortality rates and healthcare costs. The acquisition of Genetype enhances Rhythm’s capabilities in genetic risk assessment, positioning the company to meet growing demand in preventative healthcare and precision medicine markets.